Fig. 2

pS129 Immunofluorescence of PFF-injected mice. A Representative cortex, striatum, thalamus, hippocampus, and ventral midbrain images of pS129 α-synuclein positive aggregates in PFF-injected mice at 3 months p.i. B Representative cortex, striatum, thalamus, hippocampus, and ventral midbrain images of pS129 α-synuclein positive aggregates in PFF-injected mice at 6 months p.i. C Number of pS129 α-synuclein aggregates in each brain region measured using Nikon NIS elements software at 3 months (left). Multiple t-test comparison with FDR correction (Q set at 1%) revealed the number of pS129 α-synuclein aggregates was significantly higher in the ipsilateral hemisphere compared to contralateral hemisphere in the amygdala (p = 0.0003), thalamus (p = 0.0062), striatum (p = 0.0015), and insular cortex (p = 0.0046) across 3-5 sections from N = 3 PFF-injected mice. 6 months (right), pS129 quantification with Multiple t-tests with FDR correction (Q set at 1%) showed greater pS129 α-synuclein aggregates in the ipsilateral hemisphere compared to contralateral hemisphere in the amygdala (p = 0.0099), thalamus (p < 0.000001), striatum (p = 0.000002), and insular cortex (p = 0.000389). D The number of pS129 α-synuclein positive aggregates in each region was significantly decreased at 6 months compared to 3 months p.i. in the amygdala (ipsilateral p = 0.00365 and contralateral p = 0.019), as well as contralateral thalamus and insula cortex (p = 0.0378, 0.0170). E High resolution confocal imaging of pS129 α-synuclein positive inclusion morphology at 3 and 6 months p.i. in the cortex, striatum, thalamus, hippocampus, and ventral midbrain. F. pS129 α-synuclein positive inclusions were detected 6 months post intrastriatal monomer injections. Scale bars are 1000 µm for A, B, and F, and 150 µm for E